Full Lecture: [ Ссылка ]
Ryan Sullivan, MD
Massachusetts General Hospital
While immune checkpoint inhibitors may be associated with remarkable responses that may be complete and durable, most patients will not respond to therapy, and a significant minority of patients who do respond will develop disease progression. The field’s understanding into the underlying mechanisms of resistance to therapy is emerging. The objectives of this presentation are to review the clinical data supporting the use of immune checkpoint inhibitors in melanoma as a test case, review specific cases of intrinsic and acquired resistance, describe the known mechanisms of resistance, and propose potential therapies to overcome therapeutic resistance.
This is a brief overview of his talk that occurred during the 2018 Chabner Colloquium.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.
About The Chabner Colloquium:
Chaired by: Bruce A. Chabner, MD
Massachusetts General Hospital Cancer Center, Harvard Medical School.
This annual Colloquium is held in collaboration with The Massachusetts General Hospital Cancer Center and designed to focus on topics that bring cancer biology to clinical application:
- New targets and targeted agents
- Strategies for profiling and selection of patients for targeted drug trials
- Biomarkers and animal models to guide clinical development
